The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
Abstract Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-022-00394-1 |
| _version_ | 1797641223303856128 |
|---|---|
| author | Kathleen Iles Mya L. Roberson Philip Spanheimer Kristalyn Gallagher David W. Ollila Paula D. Strassle Stephanie Downs-Canner |
| author_facet | Kathleen Iles Mya L. Roberson Philip Spanheimer Kristalyn Gallagher David W. Ollila Paula D. Strassle Stephanie Downs-Canner |
| author_sort | Kathleen Iles |
| collection | DOAJ |
| description | Abstract Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across age and nodal status. Women with HR+/HER2–, early-stage (T1-2, N0-1) breast cancers from 2010–2017 in the National Cancer Database were included. 530,125 met inclusion and 255,971 received ODX testing. Older women were less likely to receive testing; however, nodal positivity increased use of testing. High ODX RS was associated with increased mortality, though the association was not consistent across age and was most strongly associated with mortality among younger, node-negative women. Older women with high ODX RS, regardless of nodal status, were less likely to receive AC. Clinicians may be employing ODX RS to support treatment decisions against the receipt of AC. |
| first_indexed | 2024-03-11T13:42:30Z |
| format | Article |
| id | doaj.art-a42beaa5870e44fab45c81312e235243 |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-11T13:42:30Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-a42beaa5870e44fab45c81312e2352432023-11-02T11:25:56ZengNature Portfolionpj Breast Cancer2374-46772022-03-01811810.1038/s41523-022-00394-1The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatmentKathleen Iles0Mya L. Roberson1Philip Spanheimer2Kristalyn Gallagher3David W. Ollila4Paula D. Strassle5Stephanie Downs-Canner6Department of Surgery, University of North Carolina at Chapel HillDepartment of Health Policy, Vanderbilt University School of MedicineDepartment of Surgical Oncology, University of North Carolina at Chapel HillDepartment of Surgical Oncology, University of North Carolina at Chapel HillDepartment of Surgical Oncology, University of North Carolina at Chapel HillDivision of Intramural Research, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of HealthDepartment of Surgical Oncology, University of North Carolina at Chapel HillAbstract Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across age and nodal status. Women with HR+/HER2–, early-stage (T1-2, N0-1) breast cancers from 2010–2017 in the National Cancer Database were included. 530,125 met inclusion and 255,971 received ODX testing. Older women were less likely to receive testing; however, nodal positivity increased use of testing. High ODX RS was associated with increased mortality, though the association was not consistent across age and was most strongly associated with mortality among younger, node-negative women. Older women with high ODX RS, regardless of nodal status, were less likely to receive AC. Clinicians may be employing ODX RS to support treatment decisions against the receipt of AC.https://doi.org/10.1038/s41523-022-00394-1 |
| spellingShingle | Kathleen Iles Mya L. Roberson Philip Spanheimer Kristalyn Gallagher David W. Ollila Paula D. Strassle Stephanie Downs-Canner The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment npj Breast Cancer |
| title | The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment |
| title_full | The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment |
| title_fullStr | The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment |
| title_full_unstemmed | The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment |
| title_short | The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment |
| title_sort | impact of age and nodal status on variations in oncotype dx testing and adjuvant treatment |
| url | https://doi.org/10.1038/s41523-022-00394-1 |
| work_keys_str_mv | AT kathleeniles theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT myalroberson theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT philipspanheimer theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT kristalyngallagher theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT davidwollila theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT pauladstrassle theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT stephaniedownscanner theimpactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT kathleeniles impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT myalroberson impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT philipspanheimer impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT kristalyngallagher impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT davidwollila impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT pauladstrassle impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment AT stephaniedownscanner impactofageandnodalstatusonvariationsinoncotypedxtestingandadjuvanttreatment |